[1]刘东玲 赵崇强 李春君 陈丽琴 邱慧娜 林静娜.2型糖尿病合并肿瘤患者血清维生素D水平 及其危险因素分析[J].国际内分泌代谢杂志,2020,40(04):217-222.[doi:10.3760/cma.j.issn.1673-4157.2020.04.001]
　Liu Dongling,Zhao Chongqiang,Li Chunjun,et al.Analysis of the level of serum vitamin D and the risk factors of patients with type 2 diabetes mellitus complicated with tumor[J].International Journal of Endocrinology and Metabolism,2020,40(04):217-222.[doi:10.3760/cma.j.issn.1673-4157.2020.04.001]
点击复制

2型糖尿病合并肿瘤患者血清维生素D水平 及其危险因素分析
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
40
期数:
2020年04期
页码:
217-222
栏目:
论著
出版日期:
2020-07-20

文章信息/Info

Title:
Analysis of the level of serum vitamin D and the risk factors of patients with type 2 diabetes mellitus complicated with tumor
作者:
刘东玲1 赵崇强2 李春君3 陈丽琴1 邱慧娜3 林静娜3
1天津市滨海新区大港医院内分泌科 300270; 2天津市第一中心医院心内科 300192; 3天津市人民医院内分泌科 300012
Author(s):
Liu Dongling1;  Zhao Chongqiang2;  Li Chunjun3;  Chen Liqin1; Qiu Huina3;  Lin Jingna3
1Department of Endocrinology,Dagang Hospital of Binhai New Area of Tianjin, Tianjin 300270, China; 2Department of Cardiovasology, Tianjin First Central Hospital, Tianjin 300192, China; 3Department of Endocrinology, Tianjin People's Hospital, Tianjin 300012, China
关键词:
2型糖尿病;  肿瘤;  25羟维生素D3
Keywords:
Type 2 diabetes mellitus;  Tumor;  25-hydroxyvitamin D3
DOI:
10.3760/cma.j.issn.1673-4157.2020.04.001
摘要:
目的 探讨2型糖尿病合并肿瘤患者的血清维生素D水平及发生肿瘤的危险因素。方法 采用病例对照研究设计,收集2016年7月1日至2018年12月31日于天津市人民医院内分泌科住院的2型糖尿病合并肿瘤患者205例作为肿瘤组,并选择同期住院不合并肿瘤的2型糖尿病患者205例作为非肿瘤组,对两组患者血清25羟维生素D3[25(OH)D3]、白蛋白、总胆固醇、钙、磷、体重指数、吸烟、饮酒、尿微量白蛋白、尿蛋白定量、肌酐、尿酸、总胆红素、谷氨酰转肽酶、碱性磷酸酶、谷草转氨酶、谷丙转氨酶、甘油三酯进行比较。应用多因素logistic回归分析,筛选2型糖尿病合并肿瘤的独立危险因素,评价危险因素对2型糖尿病合并肿瘤的预测价值。结果 与非肿瘤组相比,肿瘤组25(OH)D3水平较低(Z=-5.061,P<0.001),年龄较大(Z=-7.201,P<0.001),糖化血红蛋白较高(Z=-3.434,P=0.001),男性比例较低(χ2=6.103,P=0.013),糖尿病病程较长(Z=-2.138,P=0.033),血清白蛋白(Z=-3.448,P=0.001)、总胆固醇(Z=-2.845,P=0.004)、钙(Z=-2.007,P=0.045)、磷(Z=-2.287,P=0.022)降低,两组体重指数、吸烟、饮酒、尿微量白蛋白、尿蛋白定量、血清肌酐、尿酸、总胆红素、谷氨酰转肽酶、碱性磷酸酶、谷草转氨酶、谷丙转氨酶、甘油三酯差异无统计学意义(P均>0.05)。多因素logistic回归分析显示,25(OH)D3(OR=0.931,95% CI:0.890～0.972)、HbA1c(OR=1.178,95% CI:1.040～1.335)、年龄(OR=1.087,95% CI:1.054～1.121)、性别(OR=1.766,95% CI:1.020～3.056)是2型糖尿病患者发生肿瘤的独立危险因素,ROC曲线下面积为0.783,95% CI:0.734～0.832(P<0.001)。结论 2型糖尿病合并肿瘤患者血清25(OH)D3水平降低,且低血清25(OH)D3、高龄、女性、高糖化血红蛋白与2型糖尿病患者肿瘤发生风险增加独立相关。
Abstract:
Objective To investigate the level of serum vitamin D and the risk factors of patients with type 2 diabetes mellitus complicated with tumor.Methods A case-control study was designed to collect 205 patients with type 2 diabetes complicated with tumor who were admitted to the Department of Endocrinology in Tianjin People's Hospital from July 1, 2016 to December 31, 2018 as the tumor group, at the same time 205 patients with type 2 diabetes mellitus who were not complicated with tumor were selected as non-tumor group. Serum 25-hydroxyvitamin D3[25(OH)D3], albumin, total cholesterol, calcium, phosphorus, body mass index, smoking, drinking, urinary microalbumin, urinary protein quantity, creatine, uric acid, total bilirubin, glutamine transpeptidase, alkaline phosphatase, aspertate aminotransferase, alanine aminotransferase and triglyceride were compared between groups. Multivariate logistic regression analysis was used to screen the independent risk factors of type 2 diabetes mellitus complicated with tumor, and the predictive value of risk factors for type 2 diabetes mellitus complicated with tumor was evaluated.Results Compared with the non-tumor group, patients in the tumor group had lower levels of 25(OH)D3(Z=-5.061, P<0.001), older age(Z=-7.201, P<0.001), higher glycosylated hemoglobin(Z=-3.434, P=0.001), lower male proportion(χ2=6.103, P=0.013), longer course of diabetes mellitus(Z=-2.138, P=0.033), lower levels of serum albumin(Z=-3.448, P=0.001), total cholesterol(Z=-2.845, P=0.004), calcium(Z=-2.007, P=0.045)and phosphorus(Z=-2.287, P=0.022). There was no significant difference in body mass index, smoking, drinking, urinary microalbumin, urinary protein quantity, serum creatine, uric acid, total bilirubin, glutamine transpeptidase, alkaline phosphatase, aspertate aminotransferase, alanine aminotransferase and triglyceride between both groups(all P>0.05). Multivariate logistic regression showed that 25(OH)D3(OR=0.931, 95% CI: 0.890-0.972), glycosylated hemoglobin(OR=1.178, 95% CI: 1.040-1.335), age(OR=1.087, 95% CI: 1.054-1.121)and sex(OR=1.766, 95% CI: 1.020-3.056)were independent risk factors for type 2 diabetes mellitus patients with tumor, and the ROC curve area was 0.783, 95% CI was 0.734-0.832(P<0.001).Conclusion Serum 25(OH)D3 in patients with type 2 diabetes mellitus complicated with tumor is lower, and low serum 25(OH)D3, elderly, female and hyperglycosylated hemoglobin are independently associated with increased tumor risk in patients with type 2 diabetes mellitus.

参考文献/References:

[1] 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志,2018,38(4):34-86.DOI:10.19538/j.nk201804018.
[2] Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications[J]. Nat Rev Endocrinol,2018,14(2):88-98.DOI:10.1038/nrendo.2017.151.
[3] Chatterjee R, Erban JK, Fuss P, et al. Vitamin D supplementation for prevention of cancer:The D2d cancer outcomes(D2dCA)study[J]. Contemp Clin Trials,2019,81:62-70.DOI:10.1016/j.cct.2019.04.015.
[4] Saito E, Charvat H, Goto A, et al. Burden of cancer associated with type 2 diabetes mellitus in Japan, 2010-2030[J]. Cancer Sci,2016,107(4):521-527.DOI:10.1111/cas.12902.
[5] de Jong R, Peeters P, Burden A M, et al. Gastrointestinal cancer incidence in type 2 diabetes mellitus; results from a large population-based cohort study in the UK[J]. Cancer Epidemiol,2018,54:104-111.DOI:10.1016/j.canep.2018.04.008.
[6] Gini A, Bidoli E, Zanier L, et al. Cancer among patients with type 2 diabetes mellitus:a population-based cohort study in northeastern Italy[J]. Cancer Epidemiol,2016,41:80-87.DOI:10.1016/j.canep.2016.01.011.
[7] He X, Shi L, Wu J. Retrospective database analysis of cancer risk in patients with type 2 diabetes mellitus in China[J]. Curr Med Res Opin,2018,34(6):1089-1098.DOI:10.1080/03007995.2017.1421527.
[8] 张家庆. 重视糖尿病与癌症关系的研究[J]. 中华内分泌代谢杂志,2010,26(3):177-180.DOI:10.3760/cma.j.issn.1000-6699.2010.03.001.
[9] Shima T, Uto H, Ueki K, et al. Hepatocellular carcinoma as a leading cause of cancer-related deaths in Japanese type 2 diabetes mellitus patients[J]. J Gastroenterol,2019,54(1):64-77.DOI:10.1007/s00535-018-1494-7.
[10] Lam E, Batty G, Huxley R, et al. Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region[J]. Ann Oncol,2011,22(3):730-738.DOI:10.1093/annonc/mdq405.
[11] 周琰,潘柏申. 维生素D检测标准化进程[J]. 检验医学,2016(1):71-75.DOI:10.3969/j.issn.1673-8640.2016.01.016.
[12] Grammatiki M, Rapti E, Karras S, et al. Vitamin D and diabetes mellitus: causal or casual association?[J]. Rev Endocr Metab Disord,2017,18(2):227-241.DOI:10.1007/s11154-016-9403-y.
[13] Lu L, Bennett DA, Millwood IY, et al. Association of vitamin D with risk of type 2 diabetes:a Mendelian randomisation study in European and Chinese adults[J].Plos Medicine,2018,15(5):e1002566.DOI:10.1371/journal.pmed.1002566.
[14] Song Y, Wang L, Pittas A G, et al. Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis of prospective studies[J]. Diabetes Care,2013,36(5):1422-1428.DOI:10.2337/dc12-0962.
[15] 陈万青,孙可欣,郑荣寿,等. 2014年中国分地区恶性肿瘤发病和死亡分析[J]. 中国肿瘤,2018,27(1):1-14.DOI:CNKI:SUN:ZHLU.0.2019-01-001.
[16] David F, Krishnan AV, Srilatha S, et al. The role of vitamin D in reducing cancer risk and progression[J]. Nat Rev Cancer,2014,14(5):342-357.DOI:10.1038/nrc3691.
[17] Hossain S, Beydoun MA, Beydoun HA, et al. Vitamin D and breast cancer:a systematic review and meta-analysis of observational studies[J]. Clin Nutr ESPEN,2019,30:170-184.DOI:10.1016/j.clnesp.2018.12.085.
[18] Liu J, Dong Y, Lu C, et al. Meta-analysis of the correlation between vitamin D and lung cancer risk and outcomes[J]. Oncotarget,2017,8(46):81040-81051.DOI:10.18632/oncotarget.18766.
[19] Zhao J, Wang H, Zhang Z, et al. Vitamin D deficiency as a risk factor for thyroid cancer: a meta-analysis of case-control studies[J]. Nutrition,2019,57:5-11.DOI:10.1016/j.nut.2018.04.015.
[20] Skrajnowska D, Bobrowska-Korczak B.Potential molecular mechanisms of the anti-cancer activity of vitamin D[J]. Anticancer Res,2019,39(7):3353-3363.DOI:10.21873/anticanres.13478.
[21] Dbrowski M. Glycated hemoglobin, diabetes treatment and cancer risk in type 2 diabetes. A case-control study[J].Ann Agric Environ Med,2013,20(1):116-121.DOI:10.1029/2011GB004082.
[22] Joshu CE, Prizment AE, Dluzniewski PJ, et al. Glycated hemoglobin and cancer incidence and mortality in the atherosclerosis in communities(ARIC)Study, 1990-2006[J]. Int J Cancer,2012,131(7):1667-1677.DOI:10.1002/ijc.27394.
[23] Kim JY, Lee YS, Jo G, et al. Glycated hemoglobin and cancer risk in korean adults:results from Korean genome and epidemiology study[J].Clin Nutr Res,2018,7(3):170-177.DOI:10.7762/cnr.2018.7.3.170.

相似文献/References:

[1]曾静波,王姮.2型糖尿病与自身免疫反应[J].国际内分泌代谢杂志,2007,(04):259.
[2]朱素君,谢锦桃,刘军,等.二甲双胍：2型糖尿病治疗的基础药[J].国际内分泌代谢杂志,2007,(04):280.
[3]刘艳清 易秋艳 邵加庆.肠道菌群与肥胖和糖尿病的关系[J].国际内分泌代谢杂志,2015,(01):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
　Liu Yanqing,Yi Qiuyan,Shao Jiaqing..Relationship between gut microbiota, obesity and diabetes[J].International Journal of Endocrinology and Metabolism,2015,(04):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
[4]姚旻 赵爱源 张宏.肠道菌群与2型糖尿病[J].国际内分泌代谢杂志,2015,(01):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
　Yao Min*,Zhao Aiyuan,Zhang Hong..Relationship between gut microbiota and type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2015,(04):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
[5]赵丽娟,徐宽枫,杨涛,等.SLC30A8和PTPRD基因多态性与南京地区中老年人群2型糖尿病的相关性研究[J].国际内分泌代谢杂志,2015,(03):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
　Zhao Lijuan*,Xu Kuanfeng,Yang Tao,et al.Relationship between SLC30A8 and PTPRD gene polymorphisms and type 2 diabetes in middle aged and elderly people in Nanjing area[J].International Journal of Endocrinology and Metabolism,2015,(04):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
[6]王洁,何媛,于珮.糖尿病肾病的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
　Wang Jie*,He Yuan,Yu Pei..Risk factors of diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(04):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
[7]刘帅,张萍,方毅,等.2型糖尿病合并无症状冠状动脉钙化的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
　Liu Shuai*,Zhang Ping,Fang Yi,et al.Analysis of the risk factors related with asymptomatic coronary calcification for type 2 diabetic patients[J].International Journal of Endocrinology and Metabolism,2015,(04):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
[8]徐庆海,马颖,李铁马.2型糖尿病患者高甘油三酯血症-腰围表型与甲状腺功能异常的关系[J].国际内分泌代谢杂志,2015,(04):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
　Xu Qinghai,Ma Ying,Li Tiema..Association of hypertriglyceridaemic-waist phenotype with thyroid dysfunction in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(04):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
[9]潘道延,沈洁,朱筱,等.利格列汀对2型糖尿病大鼠代谢性内毒素血症的影响[J].国际内分泌代谢杂志,2015,(04):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
　Pan Daoyan,Shen Jie,Zhu Xiao,et al.Effects of linagliptin on metabolic endotoxemia in type 2 diabetic rats[J].International Journal of Endocrinology and Metabolism,2015,(04):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
[10]黄桥,白洁,杜洪泉.一种新的脂肪细胞因子——cartonectin[J].国际内分泌代谢杂志,2015,(04):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]
　Huang Qiao*,Bai Jie,Du Hongquan..A novel adipokine--cartonectin[J].International Journal of Endocrinology and Metabolism,2015,(04):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]

备注/Memo

备注/Memo:
通信作者:林静娜,Email:13207628978@163.com
Corresponding author: Lin Jingna, Email: 13207628978@163.com
更新日期/Last Update: 2020-07-20